215. Tetralogy of Fallot Clinical trials / Disease details
Clinical trials : 22 / Drugs : 48 - (DrugBank : 19) / Drug target genes : 18 - Drug target pathways : 49
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04713657 (ClinicalTrials.gov) | March 30, 2022 | 13/1/2021 | Beta-blocker Administration for Cardiomyocyte Division | Mechanistic Clinical Trial of Beta-Blocker Administration For Reactivating Cardiomyocyte Division In Tetrology of Fallot | Tetralogy of Fallot | Other: N-thymidine;Other: Urine Collection;Procedure: Echocardiogram;Procedure: Cardiac MRI;Drug: Propranolol Hydrochloride;Drug: Placebo;Procedure: Physical Exam;Other: Specimen Collection | Bernhard Kuhn | University of Pittsburgh | Not yet recruiting | N/A | 2 Months | All | 40 | Phase 1 | United States |